The dilemma of COVID-19 diagnosis in pregnancy

Abstract

Coronavirus Disease 2019 is a new and rapidly developing health crisis. Ongoing researches are looking at the prevalence and consequences of COVID-19 in the obstetric community and postnatal period. In COVID 19 era, pregnant mothers are prone to infection with the severe acute respiratory syndrome coronavirus 2, with a higher risk of poor pregnancy outcomes. Therefore, an accurate and early diagnosis is a necessity for this vulnerable group. Screening for asymptomatic carriers is a cornerstone to limit the COVID-19 pandemic. It is vital to evaluate patients’ clinical symptoms and epidemiological history carefully. Although the serological test; Polymerase chain reaction RT-PCR can confirm infection, it cannot determine the degree or severity of the illness. Moreover, it has false-negative results. Imaging tests allow exact diagnosis of lung damage, the severity of the disease, and the classification of patients. Comprehensive analyses of serological and imaging data will assist in the formation of an appropriate clinical diagnosis. This review will discuss the updates and critical points in establishing COVID-19 infection in pregnant women with their pros and cons.

The abundance of Interleukin-22, 37, and 38 post-vaccination and following COVID-19 recuperation

“…Only participants aged 18 years and over of both genders were included. Pregnant women (Nori W et al, 2022), diabetes, hypertension and smokers were excluded (Ahmed Saeed H et al, 2022). Baseline laboratory data for all participants included hemoglobin (Hb), red blood cell (RBC) count, platelet count, white blood cell (WBC) count and erythrocyte sedimentation rate (ESR).…”

“…Therefore, efforts have been intensified to control SARS-CoV-2 infection through the development of vaccine strategies. More than 200 COVID-19 vaccines have been developed and are either in clinical or pre-clinical trials (WHO, 2021; Hamed et al, 2022). Of these, Sinopharm (an inactivated whole-virus vaccine) and Pfizer-BioNTech (messenger RNA vaccine) have received authorization for emergency usage in various countries, including Iraq (Al Khames Aga et al, 2021).…”